SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bionoid Pharma, Inc. (BINP) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 12/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BINP
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2009 |
$-0.16 |
$0.00 |
$-3.41M |
- |
| 2010 |
$-0.13 |
$0.00 |
$-3.91M |
- |
| 2011 |
$-335.25 |
$0.00 |
$-5.14M |
- |
| 2013 |
$-46.27 |
$92.00 |
$-1.62K |
-1764.1% |
| 2019 |
$0.70 |
$56.17K |
$27.15K |
48.3% |
| 2020 |
$-11.88 |
$30.66K |
$-455.78K |
-1486.7% |
| 2021 |
$0.00 |
$102.12K |
$-135K |
-132.2% |
| 2022 |
$0.00 |
$36.04K |
$1.48K |
4.1% |
| 2023 |
$0.00 |
$37.51K |
$-7.81K |
-20.8% |
| 2024 |
$0.00 |
$0.00 |
$-317K |
- |
